Analysis of the key themes driving M&A activity reveals that precision and personalized medicine accounted for 5 pharmaceutical deals announced in Q2 2024, worth a total value of $314.4m. The $250m acquisition of Celsius Therapeutics by AbbVie was the industry’s largest disclosed deal. GlobalData’s Pharmaceuticals Industry Mergers and Acquisitions Deals by Top Themes report for Q2 2024 dissects the driving forces behind the M&A dynamics within the Pharma sector, offering essential insights into industry trends and transformations. Buy the report here.
In value terms, precision and personalized medicine-related deal activity increased by 231% in Q2 2024 compared with the previous quarter’s total of $95m and fell by 99% as compared to Q2 2023. Related deal volume increased by 150% in Q2 2024 versus the previous quarter and was 75% lower than in Q2 2023.
The top-ranked financial advisors supporting these M&A deals in H1 2024 were Fairmount Partners; Morgan Stanley; Perella Weinberg Partners with 1, 1, 1 deals respectively.
The top-ranked legal advisors supporting these M&A deals in H1 2024 were Cassels Brock & Blackwell; Fenwick & West; Meitar Law Offices with 1, 1, 1 deals respectively.
For further understanding of GlobalData's Pharmaceuticals Industry M&A Deals by Top Themes in Q2 2024 – Thematic Intelligence, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.